« Back
Home /
Ro 31-8220 (mesylate)

Ro 31-8220 (mesylate)

Item no.	HY-13866-5mg
Manufacturer	MedChem Express
CASRN	138489-18-6
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.57
Formula	C26H27N5O5S2
Citations	bioRxiv. 2024 Jul 25. EMBO Mol Med. 2022 Dec 13;e16373. Front Immunol. 2021 Feb 2;11:625542. Harvard Medical School LINCS LIBRARY Life Metab. 2025 Jan 29. Aging Cell. 2020 Oct;19(10):e13217. Aging Cell. 2022 Feb 23;e13573. Biomolecules. 2022, 12(3), 426. FASEB J. 2019 Feb;33(2):2435-2450. J Clin Invest. 2021 Dec 29;e150101. Mol Med Rep. 2017 Nov;16(5):5924-5930. Nat Commun. 2018 Sep 11;9(1):3688. Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528. [1]Wilkinson SE, et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993 Sep 1;294 (Pt 2):335-7. [2]Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. [3]Tian F, et al. Inhibition of protein kinase C protects against paraoxon-mediated neuronal cell death. Neurotoxicology. 2007 Jul;28(4):843-9. Epub 2007 Apr 20. [4]Hambleton M, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006 Aug 8;114(6):574-82.
Smiles	NC(SCCCN1C=C(C2=C(C3=CN(C)C4=C3C=CC=C4)C(NC2=O)=O)C5=C1C=CC=C5)=N.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	PKC
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	553.65
Product Description	Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.
Manufacturer - Research Area	Neurological Disease; Cardiovascular Disease; Cancer
Solubility	DMSO : 35.71 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics; TGF-beta/Smad
Isoform	PKC; PKCα; PKCβ; PKCγ; PKCε
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13866-5mg-safety-datasheet.pdf